Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as
leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal
suppression and demonstrate increased bone turnover and consequent bone loss at the hip and
spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.